News from the DGAP: Bencard Allergie GmbH: specialist allergen-specific immunotherapies address new practical recommendations for the treatment of insect venom allergies with the introduction of a user-friendly format for the product with insect venom (German)

^ DGAP-News: Bencard Allergy GmbH / Keyword (s): Miscellaneous Bencard Allergy GmbH: Specialist allergen-specific immunotherapies, address new practical recommendations for the treatment of allergic venom allergies. insect with the introduction of a user-friendly format for insect venom-based products

08.11.2018 / 10:00 The sender / publisher is responsible for the content of this announcement.

Bencard Allergie GmbH: Specialist allergen-specific immunotherapies, with the introduction of a user-friendly format for an insecticide product, address new practical recommendations for the treatment of venom allergy. # 39; insect

– Proven immunotherapy against bee venom or bee venom allergy in a new commercial form available in six single injections for administration in maintenance treatment –

– The company's bee venom product is currently one of the few preparations on the market that contains a wide range of essential allergen components of the bee –

– Bencard Allergie organizes its annual allergy symposium in Vienna from 9 to 10 November 2018 with leading international medical and scientific experts

Munich and Worthing, United Kingdom, November 8, 2018 – Bencard Allergy GmbH, a subsidiary of the international company Allergy Therapeutics plc (AIM: AGY), a pharmaceutical company specializing in allergy vaccines, announces that its solutions for the treatment of allergies Immunotherapy treat allergies to bees and wasp venom. available since autumn in a new form of trade in which six vials of 120 μg each are administered for six individual injections in maintenance treatment. Thanks to its immunotherapy against allergy to bee venom or wasp, Bencard Allergy has launched a product meeting the practical challenges of hyposensitization or specific immunotherapy at the same time. allergen (SIT) for the treatment of allergy to insect venom. This new form of trade also takes into account the current conclusion that it is preferable to use freshly prepared injection solutions for the administration of bee venom1. For patients with GKV, the long packing period of at least six months also brings financial benefits: they enjoy a reduced overall burden of the quota compared to the size of the conventional packaging .

Insect venom allergies are the most common cause of severe anaphylactic reactions in adults and are among the most dangerous allergies ever observed. Specific immunotherapy (STI) has been shown to reduce the risk of severe anaphylaxis caused by Hymenoptera bites, including wasps and bees. Up to 95% of wasp venom and up to 85% of bee venom allergies can be successfully treated with SIT.2 However, the standardization of SIT preparations, especially in the bee venom allergy field, is by no means innocuous because of the complex composition of natural extracts, For example, the natural bee venom consists of many different allergen components to which a patient may be allergic. To date, five allergenic components – Api m 1, Api m 2, Api m 3, Api m 5 and Api m 10 – have been attributed a particularly high allergic relevance13,3. Only Api m 1 is present in appreciable amounts in pure bee venom, the other allergens mentioned above are only present in small amounts. If the component used by SIT lacks the component to which the patient is allergic or is under-represented in the extract, the immune system may not be able to develop tolerance to the toxin. The clinical effectiveness of the drug is ultimately diminished.

Variations in the natural composition of the raw material as well as changes in the subsequent treatment can significantly influence the qualitative composition of the allergenic components in the TSI preparations. In practice, this leads to the fact that some commercially available preparations, used for hyposensitization of bee venom allergies, sometimes do not contain all the relevant allergens or can be difficult to detect badytically, such as recently showed a study1. In particular, the Api m 3 and Api m 10 components were under-represented in this study in some of the products studied, or even impossible to detect with the badysis method used.

In order to ensure a consistently high product standard ensuring that the five allergens listed above are included in the final product, Bencard Allergy prepares the raw material extremely smoothly. The company's bee venom product is thus one of the few on the market to contain a wide range of allergens, as shown by the same studies of Blank and Mitarbeiter1.

Dr. Conrad Weber, director of scientific marketing at Bencard Allergy GmbH, said: "Current scientific research has shown that our insecticide product is one of the few products on the market containing a wide range of individual components relevant to the In the meantime, we have been able to provide our customers with an even more user-friendly product, our proven immunotherapy against venom allergies from bees or wasps.The wide acceptance of our This range of products is also impressively supported by current market figures, increasing our product range by 35% in one year and continuing to increase our market share successfully.4 This success encourages us to further diversify our range of products. middle term. "

Create a speech to advance the immunotherapy of tomorrow In order to better inform about subcutaneous immunotherapy as well as many other strengths in the field of allergies, Bencard Allergy organizes again its symposium on the 39; allergy. Leading international medical and scientific experts will present, among others, the highlights of international congresses, the use of viral particles in the treatment of allergy to peanut, aluminum in medicine, the Therapeutic Allergy Regulations and current long-term immunotherapy data.

– END –

For more information, please contact:

Bencard Allergie GmbH / MC AG + 49-211-529252-22 Anne Hennecke [email protected]

About Allergy Therapeutics Allergy Therapeutics is an international pharmaceutical company specializing in the treatment and diagnosis of allergic diseases. These include allergen-specific immunotherapies for the treatment of pollen allergies, house dust and insect venom. The company sells its own products and the products of its subsidiaries in some 20 countries. The company's broad portfolio of development projects includes allergen-specific vaccines for the treatment of herbal, tree and mite allergies, currently in clinical development, as well as a vaccine for the treatment of peanut allergies in Europe. preclinical development. In addition, the company is also developing adjuvant systems designed to improve vaccines in other clinical areas beyond its core business, allergy.

Founded as a spin-off by Smith Kline Beecham in 1999, Allergy Therapeutics is headquartered in Worthing, UK, where it is represented in over 11,000 square meters of state-of-the-art manufacturing facilities and laboratories MHRA certified. The company has approximately 500 employees and is listed on the London Stock Exchange (AIM: AGY).

For more information, visit: www.allergytherapeutics.com.

About Bencard Allergy GmbH Bencard Allergy GmbH, a German subsidiary of the international research company Allergy Therapeutics, is a pharmaceutical company that has successfully focused on the forward-looking segment of the allergy market. The portfolio includes a wide range of therapeutic solutions and diagnostic tests for allergy diagnostics as well as for over-the-counter synbiotics. Current research activities include the development of other innovative adjuvants, for example: Bencard Adjuvant Systems' Virus-Like Particles (VLPs), an allergy program for molecular characterization of allergens and development new treatment concepts adapted to patients for perennial allergies (all year round). With a broad product portfolio and forward-looking research activities, Bencard Allergy is up-to-date and a competent partner in the field of allergology. The 80 years of the company's allergy research know-how guarantee steady growth and a positive result.

More on www.bencard.com.

sources:

1. Blank et al. (2017) Evaluation, resolved into components, of the major allergen content in therapeutic extracts for specific immunotherapy of allergy to bee venom. Hum Immunother Vaccine. 13: 2482-2489.

2. Przybilla et al. (2011) Diagnosis and treatment of allergy to bees and wasp venom. Allergo J. 20: 318-339.

3. The abbreviation for "Api m" allergen means "Apis mellifera", the scientific name of the European bee. The following number represents the allergens in the order of their initial scientific description (for example, Api m 1 was discovered before Api m 10).

4. Insight V01A Health Market Figures, September 2018 Market Segment.

08.11.2018 Distribution of a news about the company, forwarded by DGAP – a service of EQS Group AG. The content of the communication is the responsibility of the sender / publisher.

DGAP's distribution services include regulatory announcements, company / financial information and press releases. Media archive on http://www.dgap.de

742441 08.11.2018

°